Fagron NV (FAGR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Fagron NV (FAGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3427
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fagron NV (Fagron), formerly Arseus NV is a pharmaceutical compounding solution provider. The company offers products such as raw materials, extracts and tinctures, flammable products, anesthesia, ointment bases, syrups, suspension media, triturations, phyto pharmaflore, medispend, capsicards system, capsicards gelulen and consumables. It also offers dispensers, liquid preparations, semi-solid preparations, solid preparations, piluliers, pumps and consumables, among others. Fagron’s compounding services provide customized pharmaceutical products for specific patient needs. The company’s products find its application in therapeutic areas such as allergy, antibiotic, skin, and others. Fagron is headquartered in Nazareth, Belgium.

Fagron NV (FAGR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Fagron NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Fagron NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Fagron NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Fagron NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Fagron NV, Medical Devices Deals, 2012 to YTD 2018 9
Fagron NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Fagron NV, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Fagron Acquires Four Compounding Pharmacies From Quifarma 11
Partnerships 12
Fagron Enters Into Joint Venture With NxGen Pharma To Form Fagron Australia 12
Licensing Agreements 13
Omeros Enters into Licensing Agreement with Fagron 13
Equity Offering 14
Fagron Raises USD96.7 Million in Rights Offering of Shares 14
Fagron to Raise up to USD99 Million in Rights Offering of Shares 15
Fagron Raises USD147 Million in First Tranche of Private Placement of Shares 16
Fagron Raises USD10 Million in Public Offering of Shares 18
Fagron Completes Private Placement of Shares upon Exercise of Warrants 19
Debt Offering 20
Fagron Raises USD297.3 Million in Public Offering of Bonds 20
Acquisition 21
Fagron to Acquire Humco for USD70 Million 21
Fagron Acquires All Chemistry 22
Fagron to Acquire AnazaoHealth 23
Gilde Healthcare Sells its Stake in Pharmaline 24
Waterland Divests 26.67% Stake In Arseus 25
Fagron Acquires JCB Labs 26
Fagron Acquires Freedom Pharma 27
Fagron To Acquire B&B Pharma 28
Fagron Acquires Orbus Pharma, Drug Manufacturing Company 29
Fagron Acquires ApodanNordic PharmaPackaging, Provider Of Pharma Packaging Solutions 30
Fagron Acquires Florien, Medical Products Distributor 31
Fagron NV – Key Competitors 32
Fagron NV – Key Employees 33
Fagron NV – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 37
Financial Announcements 37
Aug 03, 2018: Fagron realised organic turnover growth of 8.5% 37
Corporate Communications 38
Nov 27, 2017: Fagron: Rafael Padilla succeeds Hans Stols as CEO 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Fagron NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Fagron NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Fagron NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Fagron NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Fagron NV, Deals By Therapy Area, 2012 to YTD 2018 8
Fagron NV, Medical Devices Deals, 2012 to YTD 2018 9
Fagron NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Fagron Acquires Four Compounding Pharmacies From Quifarma 11
Fagron Enters Into Joint Venture With NxGen Pharma To Form Fagron Australia 12
Omeros Enters into Licensing Agreement with Fagron 13
Fagron Raises USD96.7 Million in Rights Offering of Shares 14
Fagron to Raise up to USD99 Million in Rights Offering of Shares 15
Fagron Raises USD147 Million in First Tranche of Private Placement of Shares 16
Fagron Raises USD10 Million in Public Offering of Shares 18
Fagron Completes Private Placement of Shares upon Exercise of Warrants 19
Fagron Raises USD297.3 Million in Public Offering of Bonds 20
Fagron to Acquire Humco for USD70 Million 21
Fagron Acquires All Chemistry 22
Fagron to Acquire AnazaoHealth 23
Gilde Healthcare Sells its Stake in Pharmaline 24
Waterland Divests 26.67% Stake In Arseus 25
Fagron Acquires JCB Labs 26
Fagron Acquires Freedom Pharma 27
Fagron To Acquire B&B Pharma 28
Fagron Acquires Orbus Pharma, Drug Manufacturing Company 29
Fagron Acquires ApodanNordic PharmaPackaging, Provider Of Pharma Packaging Solutions 30
Fagron Acquires Florien, Medical Products Distributor 31
Fagron NV, Key Competitors 32
Fagron NV, Key Employees 33
Fagron NV, Subsidiaries 34

List of Figures
Fagron NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fagron NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fagron NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fagron NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fagron NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Fagron NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Fagron NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Fagron NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Fagron NV, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Fagron NV (FAGR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aeroflot Oao:企業の戦略・SWOT・財務分析
    Aeroflot Oao - Strategy, SWOT and Corporate Finance Report Summary Aeroflot Oao - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dah Chong Hong Holdings Ltd (1828):企業の財務・戦略的SWOT分析
    Dah Chong Hong Holdings Ltd (1828) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Sirti SpA:企業の戦略的SWOT分析
    Sirti SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Neoen SAS:電力:M&Aディール及び事業提携情報
    Summary Neoen SAS (Neoen), a subsidiary of Direct Energie SA, is an independent producer of sustainable energy provider. The company generates power from solar, wind and biomass. It specializes in the development, finance, construction and operation of green power plants such as wind farms, solar fa …
  • Beverages & More Inc:企業の戦略的SWOT分析
    Beverages & More Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Raia Drogasil SA:企業の戦略・SWOT・財務分析
    Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report Summary Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Teleperformance SE (TEP):企業の財務・戦略的SWOT分析
    Teleperformance SE (TEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Adaptive Biotechnologies Corp:医療機器:M&Aディール及び事業提携情報
    Summary Adaptive Biotechnologies Corp (Adaptive) specializes in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. The company’s product portfolio comprises immunoSEQ and clonoSEQ. It provides immunosequencing platform to laboratories for conductin …
  • Hudson Global Inc (HSON):企業の財務・戦略的SWOT分析
    Hudson Global Inc (HSON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • InterOil Corporation (IOC)-石油・ガス分野:企業M&A・提携分析
    Summary InterOil Corporation (InterOil) is an independent oil and gas company that carries out acquisition, exploration and development of oil and gas assets. It principally focuses on liquefied natural gas (LNG) projects in Papua New Guinea (PNG). It has several exploration licenses in the prospect …
  • Insightra Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Insightra Medical Inc (Insightra Medical), a subsidiary of GPB Life Science Holdings LLC is a medical device company that develops disposable devices. The company offers cardiovascular and surgical solutions. Its cardiovascular solutions include Ultra 7FR IAB and modulare. The Modulare Cathe …
  • Analytik Jena AG:医療機器:M&Aディール及び事業提携情報
    Summary Analytik Jena AG (Analytik Jena), a subsidiary of Endress+Hauser AG is a provider of instruments and products for analytical measuring technology and life science. The company’s major products include atomic spectrometers, optical emission spectroscopy devices, mass spectrometers, mercury an …
  • Shenzhen Moso Power Supply Technology Co Ltd (002660):電力:M&Aディール及び事業提携情報
    Summary Shenzhen Moso Power Supply Technology Co Ltd (Moso Power) is a manufacturer of electronics and electrical appliances. The company designs and distributes consumer electronics and solar photovoltaic products. Its products include LED driver, outdoor lighting, industrial lighting, landscape li …
  • Ryder System Inc (R):企業の財務・戦略的SWOT分析
    Ryder System Inc (R) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • IDL Biotech AB (IDL B):企業の財務・戦略的SWOT分析
    Summary IDL Biotech AB (IDL Biotech) is a biotechnology company that develops, manufactures and markets vitro diagnostic tests. The company offers products in the clinical areas of oncology and bacteriology. It offers vitro diagnostic tumor activity markers for common types of cancer which include b …
  • TravelCenters of America LLC:企業の戦略・SWOT・財務情報
    TravelCenters of America LLC - Strategy, SWOT and Corporate Finance Report Summary TravelCenters of America LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Multiplan Empreendimentos Imobiliarios SA:企業の戦略・SWOT・財務情報
    Multiplan Empreendimentos Imobiliarios SA - Strategy, SWOT and Corporate Finance Report Summary Multiplan Empreendimentos Imobiliarios SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Biocodex Inc-製薬・医療分野:企業M&A・提携分析
    Summary Biocodex Inc (Biocodex), a subsidiary of Biocodex is a manufacturer and distributor probiotic drug products. The company’s products include Saccharomyces boulardii CNCM I-745 that has a positive effect on the gut's microflora. It also provides Florastor, a yeast-based probiotic that helps ke …
  • Bank of Queensland Ltd (BOQ)
    Bank of Queensland Ltd (BOQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Sequella Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sequella Inc (Sequella) is a clinical-stage pharma company that develops antibiotics to address drug resistant bacterial, fungal, and parasitic infections. The company’s pipeline products comprise SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid antibiotic susceptibility test, B-SMART. S …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆